中国药物经济学
中國藥物經濟學
중국약물경제학
CHINA JOURNAL OF PHARMACEUTICAL ECONOMICS
2015年
2期
74-75
,共2页
儿童%病毒性上呼吸道感染%抗病毒药物
兒童%病毒性上呼吸道感染%抗病毒藥物
인동%병독성상호흡도감염%항병독약물
Children with viral upper respiratory infection%Virus%Drug therapy
目的:探讨儿童病毒性上呼吸道感染患者给予抗病毒药物治疗的临床疗效。方法选取2013年3月至2014年3月我院儿童病毒性上呼吸道感染患者60例,以抽签法随机分为观察组与对照组,各30例。观察组患儿给予中药抗病毒药物治疗,对照组患儿给予西药治疗,比较两组患儿的临床疗效及用药安全性。结果观察组患儿的治疗总有效率为96.7%,明显高于对照组的76.7%,差异有统计学意义(P<0.05);两组患儿用药不良反应发生率比较,差异无统计学意义(P>0.05),且Ⅲ、Ⅳ级不良症状均未发生。结论中药抗病毒药物具有疗效可靠、安全性高等优势,更适用于儿童病毒性上呼吸道感染。
目的:探討兒童病毒性上呼吸道感染患者給予抗病毒藥物治療的臨床療效。方法選取2013年3月至2014年3月我院兒童病毒性上呼吸道感染患者60例,以抽籤法隨機分為觀察組與對照組,各30例。觀察組患兒給予中藥抗病毒藥物治療,對照組患兒給予西藥治療,比較兩組患兒的臨床療效及用藥安全性。結果觀察組患兒的治療總有效率為96.7%,明顯高于對照組的76.7%,差異有統計學意義(P<0.05);兩組患兒用藥不良反應髮生率比較,差異無統計學意義(P>0.05),且Ⅲ、Ⅳ級不良癥狀均未髮生。結論中藥抗病毒藥物具有療效可靠、安全性高等優勢,更適用于兒童病毒性上呼吸道感染。
목적:탐토인동병독성상호흡도감염환자급여항병독약물치료적림상료효。방법선취2013년3월지2014년3월아원인동병독성상호흡도감염환자60례,이추첨법수궤분위관찰조여대조조,각30례。관찰조환인급여중약항병독약물치료,대조조환인급여서약치료,비교량조환인적림상료효급용약안전성。결과관찰조환인적치료총유효솔위96.7%,명현고우대조조적76.7%,차이유통계학의의(P<0.05);량조환인용약불량반응발생솔비교,차이무통계학의의(P>0.05),차Ⅲ、Ⅳ급불량증상균미발생。결론중약항병독약물구유료효가고、안전성고등우세,경괄용우인동병독성상호흡도감염。
Objective To investigate the clinical efficacy of children with viral upper respiratory tract infection patients were given antiviral therapy.Methods Methods 60 patients from 2013 March to 2014 March in our hospital of children viral upper respiratory tract infection,randomly divided into observation group and control group,each of 30 cases.Observation group were treated with traditional Chinese medicine treatment,patients in control group were treated with western medicine therapy,compared two groups of patients with drug efficacy and safety.Results Observation of patients in the treatment group the total effective rate was 96.7%,significantly higher than that in the control group 76.7%,the difference was statisticaly significant(P<0.05);the two groups of patients with drug adverse reactions rate comparison,no significant difference(P>0.05),and III,IV adverse symptoms occurred.Conclusion Traditional Chinese medicine antiviral drugs has reliable efficacy,higher safety many advantages,more suitable for use in children with viral upper respiratory tract infection of hand.